Slide 1: Company Results Summary for Q1 2025
Company Results Summary for Q1 2025 22.05.2025 r.
Slide 2: Disclaimer
This presentation (the <Presentation=) has been prepared by Celon Pharma S.A. (the <Company=) for informational purposes only and does not constitute an offer for sale or an invitation to submit offers to purchase the Company9s securities within the meaning of applicable law, in particular the Act o
Slide 3: Operating Revenues Q1 2025 (Generics Segment)
Operating Revenues Q1 2025 (Generics Segment) 45,000 35,479 30,000 28,325 15,000 13,499 7,993 0 Domestic Export Q1-2024 (tys. PLN) Q1-2025 (tys. PLN) Q1-2024 (000 PLN) Q1-2025 (000 PLN) Y/y (%) Domestic market 28 325 35 479 25% Export 7 993 13 499 69% Total 36 318 48 978 35%
Slide 4: Operational costs - Q1 2025 (Generics Segment)
Operational costs - Q12025 (Generics Segment) Q1 2024 Q1 2025 Y/y 8% Operational (35 539) (41 691) +17% costs in total 23% Depreciation & (9 111) (9 551) +5% Amortization Materials & (8 687) (12 959) +49% Energy External Services (2 404) (3 000) +25% 31% Salaries & Social (11 293) (13 069) +16% Insu
Slide 5: Operating Costs Q1 2025 (Innovative Segment)
Operating Costs Q1 2025 (Innovative Segment) 4,016 Revenues 356 0 other revenues 341 4,016 grants 15 0 1,500 3,000 4,500 Q1 2024 Q1 2025 in 000 PLN. Q1 2024 Q1 2025 Zmiana FY'25 / FY'24 Revenues in total 4 016 356 -91% Other revenues 3 341 0% Grants 4 016 15 -100%
Slide 6: Operating Costs Q1 2025 (Innovative Segment)
Operating Costs Q1 2025 (Innovative Segment) Costs structure Q1-2025 Q1-2024 Q1-2025 Zmiana FY'25 / FY'24 Operating costs (22 605) (26 222) 16% 3% 14% Depreciation & (3 617) (3 715) 3% Amortization Materials & Energy (4 390) (6 327) 44% External Services (6 279) (6 079) -3% 36% Salaries & Social (7
Slide 7: Operating costs Q1 2025 (Total)
Operating costs Q12025 (Total) Struktura kosztów operacyjnych Operating costs in details 4% Q1-2024 Q1-2025 FY'25 / FY'24 8% Operating costs (58 144) (67 913) 17% Depreciations and (12 728) (13 266) 4% 31% amortisation 15% Materials&Energy (13 077) (19 286) 47% External Services (8 683) (9 079) 5% S
Slide 8: Domestic sales - Q1 2025
Domestic sales - Q1 2025 Q1 2024 vs Q1 2025 (000 zC) 18,000 14,450 13,859 12,000 10,052 9,290 6,000 5,668 2,448 1,981 1,276 1,402 772 810 0 0 Salmex Ketrel Zarixa Donepex Valzek Aromek Q1 2024 Q1 2025
Slide 9: Domestic sales - trends 2025
Domestic sales - trends 2025 Maintaining sales trajectory Stable ex-factory sales of portfolio products. Key products Salmex and Zarixa (60% of total sales volume) Positive trends Favorable regulatory environment for Polish manufacturers. Growth outlook Tikozek market launch (Q2 2025).
Slide 10: Export - Q1 2025
Export - Q1 2025 100 50 85 New Registrations Registration in progress Portugal Mexico ( 01.2025) i RPA (03.2025) Arabia Saudyjska, Hong Kong, Chiny New inhaler launch G7 13,8 PLN mln Export sales increase 73% Yoy
Slide 11: Export - 2025
Export - 2025 New markets Renegotiations of agreements Product launches New terms of cooperation with partners Products registration Forecasted Growth Procedures in high-potential markets Recovery through fulfillment of postponed orders
Slide 12: CPL-36 Status and Development Strategy
CPL-36 3 Status and Development Strategy Advanced Licensing Discussions Indication Separation Strategy Ongoing advanced partnering negotiations, with increased interest following Differentiation through: Parkinson9s study results. modifying dosage forms for different indications, Consideration of sp
Slide 13: CPL-116 - Status and Development Strategy
CPL-116 - Status i Strategia Rozwoju ¥ Change in Development Direction Currently in discussions with a partner regarding the indication of Myasthenia Gravis. 1 ¥ Market Potential Rapidly growing market (from USD 1bn to 536bn within 3 years); no oral therapies available, significant unmet need among
Slide 14: Financing Strategy for Innovative Projects
Financing Strategy for Innovative Projects ABM Grants Signed agreement 31 mln PLN Short-term projects with expected commercial return Partnering strategy Seeking partners for advanced projects (CPL36/CPL116) Licensing Agreements 4 Development of generic drug projects
Slide 15: Contact for investors
Contact for investors Additional materials inwestorzy@celonpharma.com www.celonpharma.com